Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types

Xuan Ou; Heather A O’Leary; Hal E Broxmeyer

doi:10.1182/blood-2013-02-487470

. 2013 May 1;122(2):161–169. doi: 10.1182/blood-2013-02-487470

Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types

Xuan Ou ¹, Heather A O’Leary ¹, Hal E Broxmeyer ^1,^✉

PMCID: PMC3709652 PMID: 23637126

Abstract

Dipeptidylpeptidase (DPP) 4 has the potential to truncate proteins with a penultimate alanine, proline, or other selective amino acids at the N-terminus. DPP4 truncation of certain chemokines, colony-stimulating factors, and interleukins have recently been linked to regulation of hematopoietic stem/progenitor cells, more mature blood cells, and other cell types. We believe that the potential role of DPP4 in modification of many regulatory proteins, and their subsequent effects on numerous stem/progenitor and other cell-type functions has not been adequately appreciated. This review addresses the potential implications of the modifying effects of DPP4 on a large number of cytokines and other growth-regulating factors with either proven or putative DPP4 truncation sites on hematopoietic cells, and subsequent effects of DPP4-truncated proteins on multiple aspects of steady-state and stressed hematopoiesis, including stem/progenitor cell, and more mature cell, function.

Introduction

The physiology and pathology of organs and tissues depends on normal or disordered regulation of their inherent cell types, respectively. Hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) functions are regulated in paracrine fashion by cell-released cytokines, chemokines, and other growth-modulating factors that induce their effects through specific receptor-mediated intracellular signaling.^1-3 Such proteins also regulate other stem and progenitor cell types and influence functions of more mature cells. Although many studies have elucidated activities of these proteins for cell and intracellular effects, little effort has gone into understanding how changes in the biomolecules themselves influence steady-state or stressed cell functions in health and disease, and the roles that enzymes may play in modifying biomolecule activity. This review focuses on dipeptidylpeptidase (DPP) 4, recently shown to influence the functional activity of a number of chemokines, colony-stimulating factors (CSFs), and ILs for effects on HSCs, HPCs, and hematopoiesis.^4-6 We believe that DPP4 plays an important and under-recognized role in modifying the activities of many different proteins that influence a multitude of different cell, tissue, and organ responses via protein truncation. Herein we review information on the enzymatic activities of DPP4 and provide a large but not necessarily all-inclusive list of chemokines, other cytokines, and growth modulatory proteins with putative DPP4 truncation sites, focusing on proteins that are known to or may in the future be shown to influence blood cells, and we suggest the means by which DPP4 changes, or might change, the activities of these biomolecules.

DPP4, discovered in 1966, is a 110 Kd member of the prolyoligopeptidase family,⁷ whose crystal structure has been described in complex with a substrate analog.⁸ DPP4 functions as a serine protease, selectively cleaving the N-terminal, penultimate proline, or alanine of proteins; other amino acids, such as serine, in the second position, may also be able to be cleaved.⁹ DPP4 is found as both a type II cell surface protein (CD26) and as a soluble molecule lacking intracellular and transmembrane domains.¹⁰ DPP4 is found in serum/plasma, cerebrospinal fluid, synovial fluid, and semen.^11,12 The transmembrane form of the protein is ubiquitously expressed in many tissues including bone marrow, venular end of blood vessels, lung, spleen, pancreas, kidney, liver, intestines, and epithelial cells.^10,13 It is expressed on embryonic stem cells (ESCs),¹⁴ HSCs, and HPCs,^4,5 as well as on other more mature blood cells such as memory T cells,¹⁵ and may be expressed on other stem and progenitor cell populations.

Although DPP4 may function in a nonenzymatic way, such as described in recent reports in which CD26 is involved in infection of cells by oncoviruses,¹⁶ and situations in which natural ligands of DPP4 have been shown to enhance the production of transforming growth factor (TGF)-β on T-cell subsets,¹⁷ the enzymatic activity of DPP4 will be the focus of this review because it is important for regulation of steady-state and stressed cellular functions and has been implicated in certain disease states. DPP4 activity is increased in the plasma/serum of people with type 2 diabetes and increased on the surface of T cells in patients with arthritis,¹⁸ and increases in DPP4 have been correlated with organ transplant rejection.^19-23 Although not much is known about the regulation of DPP4, a heparin sulfate proteoglycan expressed on human and murine stem and progenitor cells, GPC-3 (glypican-3) interacts with tissue factor pathway inhibitor to act as a biological inhibitor of DPP4.²⁴ Understanding preferred targets of DPP4, how DPP4 may alter protein activities for physiological activity and disease pathophysiology,²⁵ as well as regulation of CD26 expression and its enzymatic activity is important and warrants continued investigation.

Effects of DPP4 on HSCs and HPCs

Inhibition of DPP4 enzymatic activity by small peptides such as diprotin A (ILE-PRO-ILE) or VAL-PYR on HPCs expressing CD26 enhances chemotaxis to the chemokine stromal cell–derived factor-1 (SDF-1/CXCL12)⁴ and homing and engraftment of HSCs.^5,26-31 DPP4-truncated CXCL12 was without chemotactic activity but blocked chemotaxis induced by full-length SDF-1.⁴ Pretreating target populations of human cord blood or mouse bone marrow with diprotin A or using CD26^−/− mouse target cells enhanced the CSF activities of granulocyte macrophage (GM)-CSF, granulocyte (G)-CSF, IL-3, and erythropoietin (Epo) for proliferation of HPCs.⁶ DPP4-truncated CSFs were greatly decreased in CSF activity and blunted the full-length activity of their respective CSF, both in vitro and in vivo.⁶ At least for GM-CSF, DPP4 truncated GM-CSF bound to the GM-CSF receptor (R) with higher affinity than that of full-length GM-CSF. At a lower amount of truncated to full-length GM-CSF, truncated GM-CSF competitively blocked GM-CSFR binding of full length GM-CSF, and phosphorylation of Jak2 and STAT5. Truncated GM-CSF either prevented hexamer to dodecamer formation of the GM-CSFR complex needed for full GM-CSF activity, or the truncated GM-CSF did not fully signal through the dodecamer GM-CSFR complex.⁶ Interestingly, the clinical G-CSF preparation (Neupogen) used for mobilization of HSCs and HPCs from bone marrow to blood, has a methionine placed at the N-terminus start site, thus shifting the amino acid sequence so that DPP4 could not truncate the molecule. However, a G-CSF preparation without methionine at the N-terminus, which had a DPP4 truncation site in the correct position, could be enhanced in CSF activity by pretreating target cells with diprotin A to prevent DPP4 truncation of this preparation of G-CSF.⁶ Interestingly, CD26^−/− in mice,³² or diprotin A pretreatment of mice to inhibit DPP4,³³ attenuated the HPC-mobilizing capacity of G-CSF, the mechanisms of which have not yet been fully elucidated. This activity likely does not involve direct effects of DPP4 on exogenously administered Neupogen, because, as noted before, this form of G-CSF does not have a truncation site for DPP4.

Taking into consideration effects of DPP4 inhibition on enhanced homing and engraftment of mouse HSC^5,6,26-28 and engraftment of human CD34⁺ cells^29-31 in immune-deficient mice, a pilot clinical trial assessed the effects of administration of sitagliptin (a small-molecule inhibitor of DPP4 used to treat type 2 diabetes^34,35) to patients with high-risk hematologic malignancies receiving single-unit cord blood transplants,³⁶ with encouraging but not yet conclusive results regarding enhanced time to neutrophil engraftment. With the more recent knowledge that DPP4 has negative effects on CSFs⁶ that nurture immature cell populations in the bone marrow, efforts are underway to modify the dosing schedule of sitagliptin for greater efficacy in enhancing time to engraftment of cord blood. In another transplant setting, diprotin A pretreatment of muscle-derived cells before injection significantly enhanced their engraftment and stimulated sustained proliferation of donor cells in a canine model of Duchenne muscular dystrophy.³⁷ DPP4 inhibition may also be of relevance in transplant settings for the lungs, kidney, and liver.^19-23 How these DPP4 phenomena are mechanistically manifested is yet to be determined but may involve blocking DPP4-induced truncation of different proteins.

Effects of DPP4 on leukocyte trafficking and migration

Chemokines play fundamental roles in the immune system for leukocyte trafficking, leukocyte degranulation, and angiogenesis,³⁸ and DPP4 may significantly influence chemokine activity. Similar to DPP4 effects on CXCL12,^4-6 DPP4 exerts negative feedback by decreasing the activity of CCL22/MDC. CCL22 attracts monocytes, dendritic cells, activated lymphocytes, and natural killer cells, and reportedly has anti–HIV-1 activity. DPP4-truncated CCL22 fails to desensitize calcium mobilization by full-length CCL22 or thymus- and activation-regulated chemokine in CCR4-transfected cells.³⁹ Truncated CCL22 reduces HUT-78 T-cell chemotactic activity and is 100-fold less potent than full-length CCL22.⁴⁰ Thus, N-terminal truncation of CCL22 by DPP4 differentially affects its various immunologic functions. Natural NH2-terminally truncated CCL2 (5-76) and CCL8 (6-76) are practically devoid of bioactivity. The truncated forms are potent antagonists of their full-length chemokines for chemotactic potency,⁴¹ in a manner similar to that noted for CXCL12-induced chemotaxis of HPCs.⁴ The CC chemokine, CCL11 (eotaxin), attracts eosinophils to sites of parasitic infection and allergic inflammation. Its chemotactic potency for blood eosinophils and signaling capacity through CCR3 are reduced 30-fold upon truncation by DPP4.⁴² These examples further highlight a role for DPP4 relevance during inflammation and infection, as well as in steady-state hematopoiesis.

A plethora of proteins with potential DPP4 truncation sites

To determine the extent of proteins with putative DPP4 truncation sites, we initiated a search of amino acid sequences retrieved from the National Center for Biotechnology Information (NCBI) database and from Universal Protein Resource. This search identified a large number of proteins that have a penultimate alanine, proline, or serine in the N-terminus start site. Tables 1 and 2, respectively, list chemokines/other cytokines and additional proteins with potential cell growth regulatory capacities that contain putative penultimate alanine or proline truncation sites for DPP4 activity. Table 3 highlights proteins with a putative serine truncation site. Putative truncation sites are listed for human and mouse proteins, because it is not always the case that both the human and mouse proteins have apparent DPP4 sites. Tables 1 to 3 are not meant to be all inclusive of proteins with DPP4 truncation sites but rather are to demonstrate that there are a wide variety of biologically active molecules that act on many different cell types, tissues, and organ systems that may be affected in significant ways by DPP4, especially because DPP4 is expressed on the cell surface of, and also present within, many cells and it is present in plasma and serum in soluble form.¹⁵ Whether or not all proteins listed in Tables 1 to 3 have true DPP4 truncation sites will have to be specifically determined for each of these proteins selectively via mass spectrometry or comparable analysis, and biological assays in vitro and in vivo will be required to determine whether the truncated molecules differ in functional activity from the full-length form of the protein. Classically, DPP4 is considered to cleave specifically at alanine and proline residues in the second, or penultimate, position, with little regard for the first amino acid provided it has a protinated amino group. However, some reports suggest that additional residues in the penultimate position, such as serine, could also be targets of DPP4, but these sites are considered less preferred than the proline or alanine.⁹ Importantly, certain protein modifications can alter the rate of cleavage. Proteins with proline, hydroxylproline, or N-methylglycine in the third position are thought to prevent cleavage by DPP4.⁴³ This highlights the complexity of potential DPP4 cleavage kinetics, which may differ in vitro and in vivo, and further highlights the necessity of testing the individual DPP4 cleavage potential of each protein of interest.

Table 1.

Chemokines/cytokines with putative penultimate (alanine/proline) truncation site for DPP4

Chemokines			Cytokines
Peptide	Species	N-terminus^*^†	Peptide	Species	N-terminus^*^†
CXCL1/GRO-α	M	APIAN…	Epo	H	APPRL...
CXCL2/GRO-β/MIP-2α	H	APLAT…	Epo	M	APPRL...
CXCL4/PF4	H	EAEED…	GM-CSF	H	APARS...
CXCL5/ENA-78	M	APSSV...	GM-CSF	M	APTRS...
CXCL6/GCP2	H	GPVSA...	G-CSF	H	ATPLG...
CXCL8/IL-8	H	SAKEL...	G-CSF	M	VPLVT...
CXCL9/MIG	H	TPVVR...	IL-3	H	APMTQ...
CXCL10/INP-10	H	VPLSR...	IL-1 α	H	SAPFS...
CXCL10/INP-10	M	IPLAR...	IL-1 β	H	APVRS...
CXCL11/I-TAC	H	IPLAR...	IL-1 α	M	SAPYT...
CXCL12/SDF-1	H	KPVSL...	IL-1 β	M	VPIRQ...
CXCL12 (isoform α)	M	KPVSL...	IL-2	H	APTSS...
CXCL12 (isoform β)	M	KPVSL...	IL-2	M	APTSS...
CXCL12(isoform γ)	M	QPDAI...	IL-5	H	IPTEI...
CCL2/MCP-1	H	QPDAV...	IL-6	H	VPPGE...
CCL2/MCP-1	M	APYGA...	IL-6	M	FPTSQ...
CCL3/MIP-1α/LD78α	M	APLAA...	IL-8 (6-77)	H	SAEKL...
CCL3-L1/LD78β	H	APMGS...	IL-10	H	SPGQG...
CCL4/MIP-1β	H	APMGS...	IL-13	H	GPVPP...
CCL4/MIP-1β	M	APMGS...	IL-17B	H	QPRSP...
CCL5/RANTES	H	SPYSS...	IL-17A	M	AAIIP...
CCL5/RANTES	M	SPYGS...	IL-17C	M	DPPSW...
CCL7/MCP-3	H	QPVGI...	IL-22	H	APISS...
CCL7/MCP-3	M	QPDGP...	IL-22	M	LPVNT...
CCL8/MCP-2	H	QPDSV...	IL-23 α	H	RAVPG...
CCL11/Eotaxin	H	GPASV...	IL-23 α	M	VPRSS...
CCL11/Eotaxin	M	HPGSI...	IL-27 α	H	FPRPP...
CCL12/MCP-5	M	GPDAV...	IL-27 α	M	FPTDP...
CCL16/HCC-4/LEC/LCC-1/LMC	H	QPKVP...	IL-28A	H	VPVAR...
CCL19/CKβ11/MIP-3β/ELC/Exodus-3	M	GANDA...	IL-28B	H	VPVAR...
CCL22/MDC/STCP-1	H	GPYGA...	IL-28A	M	DPVPR...
CCL22/MDC/STCP-1	M	GPYGA...	IL-28B	M	DPVPR...
CCL26/Eotaxin-3/MIP-4α	M	HPGSI...	IL-29	H	GPVPT...
CCL27/CTACK/ILC/ESKINE	M	LPLPS...

Open in a new tab

CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; Epo, erythropoietin; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-GSF, granulocytes colony-stimulating factor; IL, interleukin; Species: M = mouse, H = human.

Sequence retrieved from NCBI database.

^†

Sequence retrieved from UniProt.

Table 2.

Modulatory factors with putative penultimate (alanine/proline) truncation site for DPP4

Modulatory Factors
Peptide	Species	N-terminus^*^†	Peptide	Species	N-terminus^*^†
Adipsin (propeptide)	H	PPRGR...	IGF-1 isoform 4	M	GPETL...
Adipsin (propeptide)	M	QPRGR...	IGF-1 isoform 5	M	GPETL...
α-1 microglobulin	H	GPVPT...	Inhibin α chain (propeptide)	H	HALGG...
α-1 microglobulin	M	DPAST...	Inhibin α chain (propeptide)	M	HAVGG...
ANGPTL4 (isoform a)	H	GPVQS...	Inhibin β E chain	H	TPTCE...
ANGPTL4 (isoform b)	H	GPVQS...	Inhibin β E chain	M	TPTCE...
ANGPTL6	H	RAGAP...	Lactoferrin	M	KATTV...
BDNF (propeptide)	H	APMKE...	Leptin	H	VPIQK...
BDNF (propeptide)	M	APMKE...	Leptin	M	VPIQK...
bFGF	H	PALPE...	LIF	H	SPLPI...
bFGF	M	PALPE...	LIF	M	SPLPI...
Bradykinin	H	RPPGF...	LTα	H	LPGVG...
Bradykinin	M	RPPGF...	Neurotrophin-3	H	YAEHK...
BMP-4	H	SPKHH...	Neurotrophin-3	M	YAEHK...
BMP-4	M	SPKHH...	Notch-3	H	APPCL...
BMP-5	H	AANKR...	Notch-3	M	APPCL...
BMP-5	M	AASKR...	NPY	H	YPSKP...
c1qTNF5	H	SPPLD...	NPY	M	YPSKP...
c1qTNF5	M	SPPLD...	Oncostatin M	H	AAIGS...
Chromogranin	H	LPVNS...	Osteopontin	H	IPVKQ...
Chromogranin	M	LPVNS...	Osteopontin	M	LPVKV...
DKK3	H	APAPT...	PDGFD	M	TPQRA...
DNER	H	NPVPA...	Peptide YY	H	YPIKP...
Enterostatin	H	APGPR...	Peptide YY	M	YPAKP...
Enterostatin	M	APGPR...	Prolactin	H	LPICP...
GDF-1	H	DAEPV...	Prolactin	M	LPICS...
GDF-3	H	AAIPV...	RBP3	H	GPTHL...
GDF-3	M	AAISV...	RBP3	M	GPTHL...
GDF-5	H	APLAT...	Somatotropin isoform 1	H	FPTIP...
GDF-5	M	APLAN...	Somatotropin isoform 2	H	FPTIP...
GDF-6	H	TAFAS...	Somatotropin isoform 3	H	FPTIP...
GDF-6	M	TAFAS...	Somatotropin isoform 4	H	FPTIP...
GDF-7	H	TALAG...	Somatotropin	M	FPAMP...
GDF-7	M	TALAG...	Transferrin	H	VPDKT...
GDF-8	H	GPVDL...^§	Transferrin	M	VPDKT...
GDNF (propeptide)	H	SPDKQ...	Trypsinogen	H	APFDD...
GDNF (propeptide)	M	SPDKQ...	Vasostatin-1	H	LPVNS...
GHRH	H	YADAI...	Vasostatin-2	H	LPVNS...
GLP-1 (7-36)	H	HAEGT...	VEGF A isoform i	H	APMAE...
GLP-2	H	HADGS...	VEGF A isoform k	H	APMAE...
GRP	H	VPLPA...	VEGF A isoform l	H	APMAE...
GRP	M	APVST...	VEGF A isoform m	H	APMAE...
HCG α	H	APDVQ...	VEGF A isoform n	H	APMAE...
HCG α	M	LPDGD...	VEGF A isoform o	H	APMAE...
IGF-1 isoform 1	H	GPETL...	VEGF A isoform p	H	APMAE...
IGF-1 isoform 2	H	GPETL...	VEGF A isoform 1	M	APTTE...
IGF-1 isoform 3	H	GPETL...	VEGF A isoform 2	M	APTTE...
IGF-1 isoform 4	H	GPETL...	VEGF A isoform 3	M	APTTE...
IGF-1 isoform 1	M	GPETL...	Wnt 9b	M	AAYFG...
IGF-1 isoform 2	M	GPETL...	Wnt 10a	H	MPRSA...
IGF-1 isoform 3	M	GPETL...	Wnt 10a	M	VPRSA...

Open in a new tab

ANGPTL, angiopoietin-related protein; BDNF, brain-derived neurotrophic factor; bFGF, basis fibroblast growth factor; BMP, bone morphogenetic protein; c1qTNF5, C1q and tumor necrosis factor related protein 5; DKK, Dickkopf-related protein; DNER, Δ and notchlike epidermal growth factor–related receptor; GDF, growth differentiation factor; GDNF, glial cell line–derived neurotrophic factor; GHRH, growth-hormone–releasing hormone; GLP, glucagonlike peptide; GRP, gastrin-releasing peptide; HCG α, glycoprotein hormones α chain; IGF, insulin-like growth factor; LIF, leukemia inhibitory factor; LTα, lymphotoxin-α; Notch, neurogenic locus notch homolog protein; NPY, neuropeptide Y; PDGFD, platelet-derived growth factor D; RBP, retinol-binding protein; VEGF, vascular endothelial growth factor. Species: M = mouse, H = human.

Sequence retrieved from NCBI database.

^†

Sequence retrieved from UniProt.

^§

Sequence only retrieved from NCBI database.

Table 3.

Factors with putative truncation site (serine) for DPP4

Peptide	Species	N-terminus^*^†	Peptide	Species	N-terminus^*^†
CXCL1	H	ASVAT...	ANGPT2	M	YSNFR...
CXCL3	H	ASVVT...	BDNF	H	HSDPA...
CXCL7	H	SSTKG...	BDNF	M	HSDPA...
CXCL7	M	KSDGM...	DLL3	M	HSFGP...
CCL1	H	KSMQV...	DLL4	M	GSGIF...
CCL1	M	KSMLT...	DKK3	M	PSPTV...
CCL20	H	ASNFD...	FZD6	H	HSLFT...
CCL20	M	ASNYD...	FZD6	M	HSLFT...
IL-3	M	ASISG...	Glucagon	M	HSQGT...
IL-17E	M	VSLRI...	Glucagon	M	HSQGT...
IFN-β	H	MSYN...	GM2A	H	SSFSW...
LTα	M	LSGVR...	β NGF	H	SSSHP...
TGF-β1	H	LSTCK...	β NGF	M	SSTHP...
TGF-β1	M	LSTCK...	PACAP (1-27)	H	HSDGI...
TNF-β	M	LSGVR...	PACAP (1-38)	H	HSDGI...
TNF (membrane form)	H	MSTES...	PDGFC	M	ESNLS...
TNF (membrane form)	M	MSTES...	PDGFC	H	ESNLS...
DEK	H	MSASA...	Wnt 8a	M	ASAWS...
DEK	M	MSAAA...	Wnt 8b	H	WSVNN...

Open in a new tab

ANGPTL, angiopoietin-related protein; BDNF, brain-derived neurotrophic factor; CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; DKK, Dickkopf-related protein; DLL, Δ-like protein; Epo, erythropoietin; FZD6, frizzled-6; G-GSF, granulocytes colony-stimulating factor; GM2A, ganglioside GM2 activator; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; LTα, lymphotoxin-α; NGF, nerve growth factor; PACAP, pituitary adenylate cyclase–activating polypeptide; PDGFD, platelet-derived growth factor D; TGF, transforming growth factor; TNF, tumor necrosis factor.

Sequence retrieved from NCBI database.

^†

Sequence retrieved from UniProt.

Potential effects of DPP4 on ESCs and induced pluripotent stem (iPS) cells

In addition to HSCs, other primitive cells with the capability of both self-renewal and differentiation toward hematopoietic and other cells types, such as ESCs, have the potential to be significantly influenced by DPP4. Several soluble factors have been identified that exert functional effects on ESC self-renewal. Leukemia inhibitory factor (LIF), a member of the IL-6 family, is known to strongly promote self-renewal in mouse ESCs (mESCs).⁴⁴ LIF has a putative truncation site for DPP4 (Table 2), and CD26 is expressed on mESCs.¹⁴ Interestingly, pretreating mESCs with diprotin A enhances the LIF-induced maintenance of mESCs (Ou X, Broxmeyer HE; unpublished observations). Basic fibroblast growth factor (bFGF) is a member of the FGF family. bFGF synergizes with the BMP antagonist noggin to sustain undifferentiated proliferation of human ESCs under feeder-free conditions.^45,46 bFGF also stimulates proliferation of all cells of mesodermal origin and many cells of neuroectodermal, ectodermal, and endodermal origin. BMP4 plays well-established roles in embryonic development and lineage determination for mouse and human ESCs, as well as tissue repair. Because bFGF and BMP4 have putative truncation sites for DPP4 (Table 2), efforts are needed to determine possible roles of DPP4 in regulating FGF2 and BMP4 activities, and for determining whether inhibition of DPP4 might better promote human ESC self-renewal or pluripotency.

iPS cells^47-50can be generated via reprogramming of somatic cell types, including immature subsets of cord blood hematopoietic cells,^51,52 to an ESC-like state, and human iPS cells require proteins such as FGF2 and BMP4 for their maintenance. Because iPS cells express CD26 (O’Leary HA, Lee MR, Broxmeyer HE; unpublished observations), an investigation of inhibition of DPP4 on iPS cell generation and perhaps differentiation is also warranted.

Models for potential effects of DPP4 truncation of proteins

It is clear that we are only just beginning to elucidate the extent of DPP4 effects on hematopoiesis, stem cells, and more mature cell types. This section presents different scenarios of recognized, and also possible, effects of DPP4 truncation of proteins, shown schematically in Figures 1 and 2. Figure 1A demonstrates the possibility that truncation of a positive-acting molecule would lose a large part or all of its activity, and in addition the truncated protein would block or blunt the positive activity of the full-length protein. Examples of this are the truncated forms of SDF-1/CXCL12⁴ and of GM-CSF, G-CSF, IL-3, and Epo.⁶ These truncated proteins have significantly decreased activity and are able to block the chemotaxis, survival, and CSF activities of the full-length form of their own molecule. Such outcomes may be mediated by those already shown for GM-CSF stimulation of colony formation and subsequent induction of intracellular signaling.⁶ In this case, DPP4-truncated GM-CSF binds with higher affinity than full length GM-CSF to the GM-CSFR but does not signal well, yet it acts as a competitor (eg, dominant negative form through its blocking of the receptor binding of full-length GM-CSF). In the case of Epo, which has different target receptors and actions, it is not yet clear how DPP4 truncation may modify these different EPO functions.⁵³ Moreover, because other CSFs also have multiple targets, a role for DPP4 truncation of these CSFs and their effects on different target cell populations needs further investigation. Figure 1B presents a situation similar to that in Figure 1A, but here, a protein with suppressive activity loses most, or all, of its inhibitory activity when truncated by DPP4, and the truncated molecule blocks the suppressive activity of the full-length form of the protein, perhaps also through the truncated protein having a higher affinity for its receptor than the full-length form. Evidence for this possibility exists in that inhibition of DPP4 or CD26^−/− of target mouse bone marrow cells, or inhibition of DPP4 on cord blood, enhances the suppressive activity of selected members of the chemokine family of molecules, such as CCL2/MCP-1, CCL3/MIP-1α, CXCL4/PF4, CXCL6/GCP-2, CXCL9/MIG, and CXCL10/IP-10, on colony formation of HPC.⁵⁴ These chemokines have an alanine or proline in the penultimate N-terminus of the start site of these proteins (Table 1). Recently, we found that the DPP4-truncated forms of the chemokines assessed (CCL2, CCL3, CXCL8/IL-8, and CXCL9) lose their suppressive activity and block myelosuppression in vitro and in vivo of the respective full-length forms of their chemokine (Broxmeyer HE; unpublished observations). In both cases (Figure 1A-B), the truncated molecule acts as a competitive inhibitor or dominant negative form of the full-length molecule. This offers a potential means for feedback regulation of the action of their full length molecules. There is also the possibility that truncation by DPP4 may further enhance the stimulatory or inhibitory activity of a molecule beyond that of the full-length version of that molecule (Figure 1C), although examples of this have not yet been shown.

**Potential enhancement or inhibition resulting from DPP4 interactions with regulatory proteins.** (A) Molecules that are stimulatory in the full-length form may lose activity after DPP4 truncation and act as competitive inhibitors by diminishing the function of the full-length protein through binding to the cognate receptor with higher affinity than that of the full-length molecule. (B) Molecules that are inhibitory in the full-length form may lose their suppressive ability when truncated by DPP4 and by binding to the cognate receptor with higher affinity, allowing for blockage of the full-length molecule’s suppressive activity. (C) Stimulatory or inhibitory molecules may increase their efficacy when truncated.

**Additional possibilities for functional consequences of DPP4 truncation of regulatory proteins.** (A) Truncated molecules do not bind to their receptor and may signal through other receptors. An example of this is full-length GLP-1, which binds to its cognate receptor but is truncated quickly and subsequently is unable to efficiently bind to the GLP-1 receptor and therefore does not inhibit, or alter the function, of the full-length molecule. Exenatide (Byetta) is a synthetic GLP-1 agonist made to mimic the GLP-1 homolog extendin-4, found in the saliva of the Gila monster. Exenatide is used in the treatment of type 2 diabetes because it is stable, binds to the GLP-1 receptor to induce insulin secretion, and is resistant to DPP4 truncation. (B) Factors without truncation sites may regulate factors with truncation sites by altering their expression, or function, and proteins with DPP4 truncation sites may regulate expression of proteins with or without DPP4 truncation sites.

Figure 2A delineates a scenario in which the truncated protein binds to a receptor different from that bound by the full-length protein, a known situation for glucagon-like peptide-1 (GLP-1), a strong antihyperglycemic hormone that induces insulin secretion in a glucose-dependent manner (insulinotropic) and inhibits glucagon secretion. This model could possibly define other molecules, including those active on hematopoietic cells. For GLP-1, this results in the truncated form not inhibiting the full-length form but allows for alterative signaling of the truncated form, potentially through increased binding affinity for another receptor. GLP is rapidly truncated (>98% in ∼3 minutes in vivo), and truncated GLP either binds to the receptor with extremely low affinity (1% that of the full-length form) or not at all.^55,56 Truncated GLP-1 does not have the insulinotropic effects seen with full-length GLP-1, but it shows non–GLP-1R-mediated cardioprotective effects.⁵⁷ This has been shown to be relevant in type 2 diabetes, where DPP4 activity is elevated, and the ability of GLP-1 or other molecules to exert their effects may be diminished. We have evidence that DPP4 activity within bone marrow cells, but not within the serum, is increased after the stress of high- and low-dose nonlethal radiation,⁶ and this may occur during other situations that stress the hematopoietic system. In such cases, proteins that are N-terminally modified or have greater affinity for the receptors of interest would be of clinical use, as is the case for GLP-1 and extendin-4, and perhaps for Neupogen, which has a methione at the N-terminus that shifted the amino acid sequences away from that of a DPP4-truncatable site. Extendin-4 is a homologous protein of GLP-1, found in 1992 and isolated from the saliva of a Gila monster, that has agonist activity with GLP-1.^58,59 Extendin-4 was used as the basis for development of exenatide (Byetta), a synthetic drug that is unable to be truncated by DPP4, has higher affinity for the GLP-1 receptor than that of full-length GLP-1, and is currently used clinically in patients with type 2 diabetes with the same glucose regulation and insulinotropic effects as GLP-1, but without potential for DPP4 inhibition.⁶⁰

Other models exist such that factors without truncation sites may regulate factors with truncation sites by altering their expression, or function, and proteins with DPP4 truncation sites may regulate expression of proteins with or without truncation sites (Figure 2B). Several proteins without putative DPP4 truncation sites regulate proteins with DPP4 sites and therefore have the potential to alter multiple cell types and processes as well as potentially increasing or decreasing cellular activity/expression of DPP4/CD26. TGF-β1 does not have a DPP4 truncation site but regulates IGF-1 in mesenchymal stromal cells and osteoblasts, resulting in suppression of osteoblast differentiation.⁶¹ TGF-β1 increases expression of VEGF.^62,63 TGF-β1 and IL-13 have been shown in the context of inflammation to act synergistically to increase the expression of CCL11.⁶⁴ Of note, IGF-1, VEGF, IL-13, and CCL11 have putative DPP4 truncation sites (Tables 1 and 2), suggesting that a multitude of interactions between factors with and without DPP4 truncation sites as well as DPP4 truncation of these factors may be relevant in physiological models and chronic conditions such as inflammation. Also to be considered are effects of DPP4-truncated proteins on the production/release of other proteins (eg, IL-1, IL-6, IL-8, CSFs, etc), as well as the potential synergistic or suppressive effects that may be inherent when combinations of proteins are working in collaboration to elicit biological effects. As some examples of this, regulation of HSCs and hematopoiesis relies on interactions with cells of the bone marrow microenvironment, which produce cytokines, chemokines, and other growth-modulating factors, some of which have putative DPP4 truncation sites or are regulated by proteins that have such truncation sites. Parathyroid hormone (PTH) and osteopontin (OPN) regulate Notch and Jagged levels, and subsequently the number of osteoblasts in the niche, resulting in alterations in HSC numbers.^65-67 In addition to the role that osteoblasts play in the maintenance of HSCs, they also play a critical role in B lymphopoiesis via CXCL12, IL-7, stem cell factor (SCF), IL-6, and IL-3, and for erythropoiesis via HIF pathway modulation of EPO.^68,69 With new insight into the proteins that can potentially be cleaved by DPP4 (Tables 1-3), this raises interesting speculation about what we really know, or do not know, about niche regulation and how full length vs truncated cytokines may regulate both numbers and lineage distribution of the supportive and hematopoietic cells in the niche. For example, PTH, which does not have a truncation site, is a negative regulator of DPP4 and allows for stem-cell mobilization from the bone marrow to sites of ischemic injury.⁷⁰ Proteins such as CXCL12, OPN, EPO, IL-6, and IL-3, which are important in niche regulation potentially via PTH, have putative DPP4 truncation sites (Tables 1-3), whereas others (Notch-1, Jagged-1, IL-7) do not. Thus, some of the factors regulating the niche may be acting via their truncated, not full-length, forms. For example, OPN is a bone matrix protein expressed by both osteoblasts and osteoclasts and is contextual in its regulation of HSCs, with publications suggesting both negative and positive regulation of HSCs.^66,67 OPN is N-terminally cleaved by thrombin, which results in its chemoattractant properties,⁷¹ suggesting that it may also be regulated by N-terminal cleavage by DPP4, leading to alterations in function. Recent studies, investigating stem cell fate in the vascular niche have elucidated the importance of SCF and pleiotropin, which do not have DPP4 truncation sites. When SCF was deleted from endothelial cells or leptin receptor–expressing perivascular stromal cells, HSC numbers were diminished, and after myelosuppression, bone marrow HSC were decreased and hematopoietic regeneration blunted in PTH (^−/−) mice.^72,73 Of interest here is that leptin has a putative DPP4 truncation site (Table 2). Endothelial cells are important for hematopoiesis.^74,75 Pleiotropin induces transdifferentiation of monocytes into functional endothelial cells and is itself regulated by platelet-derived growth factor (PDGF) and nerve growth factor (NGF),⁷⁶ both of which have a putative DPP4 truncation site (Tables 2 and 3). In addition, endothelial progenitor cells (EPCs) are mobilized from the marrow to sites of ischemia, tumors, and so on, via G-CSF, GM-CSF, FGF, OPN, CCL5, CCL2, and CXCL12^77,78 (all of which contain putative DPP4 truncation sites). EPCs act directly to form vessels or have an indirect function by secreting angiogenic factors. CXCL12 (DPP4 truncation site)-induced chemotaxis of EPCs can be enhanced with IL-3 (DPP4 truncation site), and EPC function can be modulated by angiopoietin-2, VEGF, CCL11, and CXCL1 (which have putative DPP4 truncation sites), which can lead to neovascularization, angiogenesis, and repair from ischemic injury,^79,80 processes that involve blood cells.

Conclusions

A large, but not yet all inclusive, number of biologically active proteins with putative truncation sites for DPP4 has been identified, presenting many unanswered questions regarding how this ubiquitous enzyme may modulate many different hematopoietic and other cell functions through its effects on different cytokines, chemokines, and other proteins.⁸¹ In addition, it is important that the protein sequences in the databases, with putative DPP4 truncation sites, be checked frequently to ensure that the sequences have not been updated. For example, the sequence for TGF-β originally showed a DPP4 truncation site; however, the sequence has recently been modified and no longer shows a DPP4 site. Ultimately, biochemical and biological (in vitro and in vivo) studies are needed to verify for each protein whether the putative DPP4 truncation sites are true truncation sites, especially with regard to differing alanine, proline, serine, or other potential DPP4 truncation sites at the N-terminus of each molecule. If so, it is important to determine whether the truncated form is or is not changed in activity from that of its full-length form and whether the truncated form influences the activity of the full-length form, and if so, what that influence is. Such efforts could be extremely rewarding in terms of increased understanding of the in vitro and in vivo regulation of many stem, progenitor, and more mature hematopoietic and other types of cells. This information could have therapeutic relevance.

Acknowledgments

H.A.O. is supported by a postdoctoral stipend to H.E.B. from the National Institutes of Health (T32 DK07519). The laboratory work of these investigators is supported by Public Health Service Grants from the National Institutes of Health: R01 HL056416, R01 HL67384, R01 HL112669, P01 DK090948 (H.E.B.)

Authorship

Contribution: All authors were involved in the concepts, writing, and editing of this study.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Hal E. Broxmeyer, Department of Microbiology and Immunology, Indiana University School of Medicine, 950 West Walnut St, R2-302, Indianapolis, IN 46202-5181; e-mail: hbroxmey@iupui.edu.

References

1.Shaheen M, Broxmeyer HE. The humoral regulation of hematopoiesis. In: Benz EJ Jr, Shattil SJ, Furie B, et al., editors. Hematology: Basic Principles and Practice Hoffman, R. 5th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009. pp. 253–275. [Google Scholar]
2.Shaheen M, Broxmeyer HE. Hematopoietic cytokines and growth factors. In: Broxmeyer HE, editor. Cord Blood Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press; 2011. pp. 35–74. [Google Scholar]
3.Shaheen M, Broxmeyer HE. Principles of Cytokine Signaling. In: Benz EJ Jr, Silberstein LE, Heslop H, Weitz J, Anastasi J, editors. Hematology: Basic Principles and Practice Hoffman, R. 6th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2012. pp. 136–146. [Google Scholar]
4.Christopherson KW, II, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002;169(12):7000–7008. doi: 10.4049/jimmunol.169.12.7000. [DOI] [PubMed] [Google Scholar]
5.Christopherson KW, II, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305(5686):1000–1003. doi: 10.1126/science.1097071. [DOI] [PubMed] [Google Scholar]
6.Broxmeyer HE, Hoggatt J, O’Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786–1796. doi: 10.1038/nm.2991. [DOI] [PMC free article] [PubMed] [Google Scholar]
7.Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966;7(3):197–201. doi: 10.1007/BF00577838. [DOI] [PubMed] [Google Scholar]
8.Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol. 2003;10(1):19–25. doi: 10.1038/nsb882. [DOI] [PubMed] [Google Scholar]
9.Martin RA, Cleary DL, Guido DM, Zurcher-Neely HA, Kubiak TM. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim Biophys Acta. 1993;1164(3):252–260. doi: 10.1016/0167-4838(93)90256-q. [DOI] [PubMed] [Google Scholar]
10.Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209–294. doi: 10.1080/713609354. [DOI] [PubMed] [Google Scholar]
11.Solau-Gervais E, Zerimech F, Lemaire R, Fontaine C, Huet G, Flipo RM. Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 2007;36(5):373–377. doi: 10.1080/03009740701340172. [DOI] [PubMed] [Google Scholar]
12.Lambeir AM, Díaz Pereira JF, Chacón P, et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Biochim Biophys Acta. 1997;1340(2):215–226. doi: 10.1016/s0167-4838(97)00045-9. [DOI] [PubMed] [Google Scholar]
13.Grim M, Carlson BM. Alkaline phosphatase and dipeptidylpeptidase IV staining of tissue components of skeletal muscle: a comparative study. J Histochem Cytochem. 1990;38(12):1907–1912. doi: 10.1177/38.12.1701462. [DOI] [PubMed] [Google Scholar]
14.Guo Y, Hangoc G, Bian H, Pelus LM, Broxmeyer HE. SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells. 2005;23(9):1324–1332. doi: 10.1634/stemcells.2005-0085. [DOI] [PubMed] [Google Scholar]
15.Campbell TB, Broxmeyer HE. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci. 2008;13:1795–1805. doi: 10.2741/2800. [DOI] [PubMed] [Google Scholar]
16.Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254. doi: 10.1038/nature12005. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Preller V, Gerber A, Wrenger S, et al. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol. 2007;178(7):4632–4640. doi: 10.4049/jimmunol.178.7.4632. [DOI] [PubMed] [Google Scholar]
18.Ellingsen T, Hornung N, Møller BK, Hjelm-Poulsen J, Stengaard-Pedersen K. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol. 2007;66(4):451–457. doi: 10.1111/j.1365-3083.2007.01966.x. [DOI] [PubMed] [Google Scholar]
19.Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg. 2012;41(5):1166–1173. doi: 10.1093/ejcts/ezr180. [DOI] [PubMed] [Google Scholar]
20.Wieland E, Shipkova M, Martius Y, Hasche G, Klett C, Bolley R, Olbricht CJ. Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: a single-center pilot study. Ther Drug Monit. 2011;33(3):341–349. doi: 10.1097/FTD.0b013e3182188675. [DOI] [PubMed] [Google Scholar]
21.Jungraithmayr W, Oberreiter B, De Meester I, et al. The effect of organ-specific CD26/DPP IV enzymatic activity inhibitor-preconditioning on acute pulmonary allograft rejection. Transplantation. 2009;88(4):478–485. doi: 10.1097/TP.0b013e3181b08e77. [DOI] [PubMed] [Google Scholar]
22.Korom S, de Meester I, Belyaev A, Schmidbauer G, Schwemmle K. CD26/DPP IV in experimental and clinical organ transplantation. Adv Exp Med Biol. 2003;524:133–143. doi: 10.1007/0-306-47920-6_17. [DOI] [PubMed] [Google Scholar]
23.Korom S, De Meester I, Coito AJ, et al. CD26/DPP IV-mediated modulation of acute rejection. Transplant Proc. 1999;31(1-2):873. doi: 10.1016/s0041-1345(98)01812-0. [DOI] [PubMed] [Google Scholar]
24.Khurana S, Margamuljana L, Joseph C, Schouteden S, Buckley SM, Verfaillie CM. Glypican-3 mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance. Blood. 2013;121(14):2587–2595. doi: 10.1182/blood-2012-09-456715. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Laudes M, Oberhauser F, Schulte DM, et al. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. Exp Clin Endocrinol Diabetes. 2010;118(8):473–477. doi: 10.1055/s-0030-1249014. [DOI] [PubMed] [Google Scholar]
26.Tian C, Bagley J, Forman D, Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther. 2006;13(7):652–658. doi: 10.1038/sj.gt.3302695. [DOI] [PubMed] [Google Scholar]
27.Wyss BK, Donnelly AF, Zhou D, Sinn AL, Pollok KE, Goebel WS. Enhanced homing and engraftment of fresh but not ex vivo cultured murine marrow cells in submyeloablated hosts following CD26 inhibition by Diprotin A. Exp Hematol. 2009;37(7):814–823. doi: 10.1016/j.exphem.2009.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Peranteau WH, Endo M, Adibe OO, Merchant A, Zoltick PW, Flake AW. CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. Blood. 2006;108(13):4268–4274. doi: 10.1182/blood-2006-04-018986. [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev. 2007;16(3):347–354. doi: 10.1089/scd.2007.9995. [DOI] [PubMed] [Google Scholar]
30.Christopherson KW, 2nd, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 2007;16(3):355–360. doi: 10.1089/scd.2007.9996. [DOI] [PubMed] [Google Scholar]
31.Kawai T, Choi U, Liu PC, Whiting-Theobald NL, Linton GF, Malech HL. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev. 2007;16(3):361–370. doi: 10.1089/scd.2007.9997. [DOI] [PubMed] [Google Scholar]
32.Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol. 2003;31(11):1126–1134. doi: 10.1016/j.exphem.2003.07.002. [DOI] [PubMed] [Google Scholar]
33.Christopherson KW, II, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood. 2003;101(12):4680–4686. doi: 10.1182/blood-2002-12-3893. [DOI] [PubMed] [Google Scholar]
34.Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612–4619. doi: 10.1210/jc.2006-1009. [DOI] [PubMed] [Google Scholar]
35.Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46(8):876–886. doi: 10.1177/0091270006289850. [DOI] [PubMed] [Google Scholar]
36.Farag SS, Srivastava S, Messina-Graham S, et al. In-vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22(7):1007–1015. doi: 10.1089/scd.2012.0636. [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Parker MH, Loretz C, Tyler AE, Snider L, Storb R, Tapscott SJ. Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation. Skelet Muscle. 2012;2(1):4. doi: 10.1186/2044-5040-2-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Blanchet X, Langer M, Weber C, Koenen RR, von Hundelshausen P. Touch of chemokines. Front Immunol. 2012;3:175. doi: 10.3389/fimmu.2012.00175. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 1999;274(7):3988–3993. doi: 10.1074/jbc.274.7.3988. [DOI] [PubMed] [Google Scholar]
40.Struyf S, Proost P, Sozzani S, et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol. 1998;161(6):2672–2675. [PubMed] [Google Scholar]
41.Proost P, Struyf S, Couvreur M, et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol. 1998;160(8):4034–4041. [PubMed] [Google Scholar]
42.Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol. 1999;162(8):4903–4909. [PubMed] [Google Scholar]
43.Wrenger S, Reinhold D, Hoffmann T, et al. The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. FEBS Lett. 1996;383(3):145–149. doi: 10.1016/0014-5793(96)00221-9. [DOI] [PubMed] [Google Scholar]
44.Smith AG, Heath JK, Donaldson DD, et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 1988;336(6200):688–690. doi: 10.1038/336688a0. [DOI] [PubMed] [Google Scholar]
45.Xu RH, Peck RM, Li DS, Feng X, Ludwig T, Thomson JA. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods. 2005;2(3):185–190. doi: 10.1038/nmeth744. [DOI] [PubMed] [Google Scholar]
46.Yu P, Pan G, Yu J, Thomson JA. FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. Cell Stem Cell. 2011;8(3):326–334. doi: 10.1016/j.stem.2011.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
47.Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. doi: 10.1016/j.cell.2006.07.024. [DOI] [PubMed] [Google Scholar]
48.Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar]
49.Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920. doi: 10.1126/science.1151526. [DOI] [PubMed] [Google Scholar]
50.Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678–684. doi: 10.1016/j.stem.2012.05.005. [DOI] [PubMed] [Google Scholar]
51.Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell. 2010;6(1):21–24. doi: 10.1016/j.stem.2009.12.008. [DOI] [PubMed] [Google Scholar]
52.Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773–4777. doi: 10.1182/blood-2011-01-330514. [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med. 2013;210(2):205–208. doi: 10.1084/jem.20122760. [DOI] [PMC free article] [PubMed] [Google Scholar]
54.Broxmeyer HE, Campbell TB, Cooper S, Hangoc G. Inhibition/Depletion of CD26/DPPIV Enhances Survival Promoting Activity of SDF-1/CXCL12 and Myelosuppressive Activities of Inhibitory Chemokines on Hematopoietic Progenitor Cells. Blood. 2007;110(Suppl Part 1):188A. (abstract #610). 2007. [Google Scholar]
55.Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–1131. doi: 10.2337/diab.44.9.1126. [DOI] [PubMed] [Google Scholar]
56.Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem. 1997;272(34):21201–21206. doi: 10.1074/jbc.272.34.21201. [DOI] [PubMed] [Google Scholar]
57.Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–2350. doi: 10.1161/CIRCULATIONAHA.107.739938. [DOI] [PubMed] [Google Scholar]
58.Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402–7405. [PubMed] [Google Scholar]
59.Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650–19655. [PubMed] [Google Scholar]
60.López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem. 2003;278(12):10195–10200. doi: 10.1074/jbc.M212147200. [DOI] [PubMed] [Google Scholar]
61.Ochiai H, Okada S, Saito A, et al. Inhibition of insulin-like growth factor-1 (IGF-1) expression by prolonged transforming growth factor-β1 (TGF-β1) administration suppresses osteoblast differentiation. J Biol Chem. 2012;287(27):22654–22661. doi: 10.1074/jbc.M111.279091. [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Nagineni CN, Samuel W, Nagineni S, et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol. 2003;197(3):453–462. doi: 10.1002/jcp.10378. [DOI] [PubMed] [Google Scholar]
63.Renner U, Lohrer P, Schaaf L, et al. Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology. 2002;143(10):3759–3765. doi: 10.1210/en.2002-220283. [DOI] [PubMed] [Google Scholar]
64.Zhou X, Hu H, Balzar S, Trudeau JB, Wenzel SE. MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts. J Immunol. 2012;188(12):6046–6054. doi: 10.4049/jimmunol.1102760. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–846. doi: 10.1038/nature02040. [DOI] [PubMed] [Google Scholar]
66.Stier S, Ko Y, Forkert R, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005;201(11):1781–1791. doi: 10.1084/jem.20041992. [DOI] [PMC free article] [PubMed] [Google Scholar]
67.Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106(4):1232–1239. doi: 10.1182/blood-2004-11-4422. [DOI] [PubMed] [Google Scholar]
68.Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63–74. doi: 10.1016/j.cell.2012.01.051. [DOI] [PMC free article] [PubMed] [Google Scholar]
69.Zhu J, Garrett R, Jung Y, et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007;109(9):3706–3712. doi: 10.1182/blood-2006-08-041384. [DOI] [PubMed] [Google Scholar]
70.Huber BC, Brunner S, Segeth A, et al. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. Cardiovasc Res. 2011;90(3):529–537. doi: 10.1093/cvr/cvr014. [DOI] [PubMed] [Google Scholar]
71.Grassinger J, Haylock DN, Storan MJ, et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood. 2009;114(1):49–59. doi: 10.1182/blood-2009-01-197988. [DOI] [PubMed] [Google Scholar]
72.Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457–462. doi: 10.1038/nature10783. [DOI] [PMC free article] [PubMed] [Google Scholar]
73.Istvanffy R, Kröger M, Eckl C, et al. Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. Blood. 2011;118(10):2712–2722. doi: 10.1182/blood-2010-05-287235. [DOI] [PubMed] [Google Scholar]
74.Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell. 2010;6(3):251–264. doi: 10.1016/j.stem.2010.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
75.Hooper AT, Butler JM, Nolan DJ, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009;4(3):263–274. doi: 10.1016/j.stem.2009.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
76.Sharifi BG, Zeng Z, Wang L, et al. Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26(6):1273–1280. doi: 10.1161/01.ATV.0000222017.05085.8e. [DOI] [PMC free article] [PubMed] [Google Scholar]
77.George AL, Bangalore-Prakash P, Rajoria S, et al. Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol. 2011;4:24. doi: 10.1186/1756-8722-4-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
78.Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 2008;22(5):559–574. doi: 10.1101/gad.1636908. [DOI] [PMC free article] [PubMed] [Google Scholar]
79.Salcedo R, Young HA, Ponce ML, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol. 2001;166(12):7571–7578. doi: 10.4049/jimmunol.166.12.7571. [DOI] [PubMed] [Google Scholar]
80.Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther. 2012;136(3):267–282. doi: 10.1016/j.pharmthera.2012.07.012. [DOI] [PubMed] [Google Scholar]
81.O’Leary HA. *, Ou X*, Broxmeyer HE. The role of dipeptidyl peptidase 4 (DPP4) in hematopoiesis and transplantation. Curr Opin Hematol. 2013 doi: 10.1097/MOH.0b013e32836125ac. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]

[B1] 1.Shaheen M, Broxmeyer HE. The humoral regulation of hematopoiesis. In: Benz EJ Jr, Shattil SJ, Furie B, et al., editors. Hematology: Basic Principles and Practice Hoffman, R. 5th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009. pp. 253–275. [Google Scholar]

[B2] 2.Shaheen M, Broxmeyer HE. Hematopoietic cytokines and growth factors. In: Broxmeyer HE, editor. Cord Blood Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press; 2011. pp. 35–74. [Google Scholar]

[B3] 3.Shaheen M, Broxmeyer HE. Principles of Cytokine Signaling. In: Benz EJ Jr, Silberstein LE, Heslop H, Weitz J, Anastasi J, editors. Hematology: Basic Principles and Practice Hoffman, R. 6th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2012. pp. 136–146. [Google Scholar]

[B4] 4.Christopherson KW, II, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002;169(12):7000–7008. doi: 10.4049/jimmunol.169.12.7000. [DOI] [PubMed] [Google Scholar]

[B5] 5.Christopherson KW, II, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305(5686):1000–1003. doi: 10.1126/science.1097071. [DOI] [PubMed] [Google Scholar]

[B6] 6.Broxmeyer HE, Hoggatt J, O’Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786–1796. doi: 10.1038/nm.2991. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B7] 7.Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966;7(3):197–201. doi: 10.1007/BF00577838. [DOI] [PubMed] [Google Scholar]

[B8] 8.Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol. 2003;10(1):19–25. doi: 10.1038/nsb882. [DOI] [PubMed] [Google Scholar]

[B9] 9.Martin RA, Cleary DL, Guido DM, Zurcher-Neely HA, Kubiak TM. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim Biophys Acta. 1993;1164(3):252–260. doi: 10.1016/0167-4838(93)90256-q. [DOI] [PubMed] [Google Scholar]

[B10] 10.Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209–294. doi: 10.1080/713609354. [DOI] [PubMed] [Google Scholar]

[B11] 11.Solau-Gervais E, Zerimech F, Lemaire R, Fontaine C, Huet G, Flipo RM. Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 2007;36(5):373–377. doi: 10.1080/03009740701340172. [DOI] [PubMed] [Google Scholar]

[B12] 12.Lambeir AM, Díaz Pereira JF, Chacón P, et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Biochim Biophys Acta. 1997;1340(2):215–226. doi: 10.1016/s0167-4838(97)00045-9. [DOI] [PubMed] [Google Scholar]

[B13] 13.Grim M, Carlson BM. Alkaline phosphatase and dipeptidylpeptidase IV staining of tissue components of skeletal muscle: a comparative study. J Histochem Cytochem. 1990;38(12):1907–1912. doi: 10.1177/38.12.1701462. [DOI] [PubMed] [Google Scholar]

[B14] 14.Guo Y, Hangoc G, Bian H, Pelus LM, Broxmeyer HE. SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells. 2005;23(9):1324–1332. doi: 10.1634/stemcells.2005-0085. [DOI] [PubMed] [Google Scholar]

[B15] 15.Campbell TB, Broxmeyer HE. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci. 2008;13:1795–1805. doi: 10.2741/2800. [DOI] [PubMed] [Google Scholar]

[B16] 16.Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254. doi: 10.1038/nature12005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B17] 17.Preller V, Gerber A, Wrenger S, et al. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol. 2007;178(7):4632–4640. doi: 10.4049/jimmunol.178.7.4632. [DOI] [PubMed] [Google Scholar]

[B18] 18.Ellingsen T, Hornung N, Møller BK, Hjelm-Poulsen J, Stengaard-Pedersen K. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol. 2007;66(4):451–457. doi: 10.1111/j.1365-3083.2007.01966.x. [DOI] [PubMed] [Google Scholar]

[B19] 19.Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg. 2012;41(5):1166–1173. doi: 10.1093/ejcts/ezr180. [DOI] [PubMed] [Google Scholar]

[B20] 20.Wieland E, Shipkova M, Martius Y, Hasche G, Klett C, Bolley R, Olbricht CJ. Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: a single-center pilot study. Ther Drug Monit. 2011;33(3):341–349. doi: 10.1097/FTD.0b013e3182188675. [DOI] [PubMed] [Google Scholar]

[B21] 21.Jungraithmayr W, Oberreiter B, De Meester I, et al. The effect of organ-specific CD26/DPP IV enzymatic activity inhibitor-preconditioning on acute pulmonary allograft rejection. Transplantation. 2009;88(4):478–485. doi: 10.1097/TP.0b013e3181b08e77. [DOI] [PubMed] [Google Scholar]

[B22] 22.Korom S, de Meester I, Belyaev A, Schmidbauer G, Schwemmle K. CD26/DPP IV in experimental and clinical organ transplantation. Adv Exp Med Biol. 2003;524:133–143. doi: 10.1007/0-306-47920-6_17. [DOI] [PubMed] [Google Scholar]

[B23] 23.Korom S, De Meester I, Coito AJ, et al. CD26/DPP IV-mediated modulation of acute rejection. Transplant Proc. 1999;31(1-2):873. doi: 10.1016/s0041-1345(98)01812-0. [DOI] [PubMed] [Google Scholar]

[B24] 24.Khurana S, Margamuljana L, Joseph C, Schouteden S, Buckley SM, Verfaillie CM. Glypican-3 mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance. Blood. 2013;121(14):2587–2595. doi: 10.1182/blood-2012-09-456715. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B25] 25.Laudes M, Oberhauser F, Schulte DM, et al. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. Exp Clin Endocrinol Diabetes. 2010;118(8):473–477. doi: 10.1055/s-0030-1249014. [DOI] [PubMed] [Google Scholar]

[B26] 26.Tian C, Bagley J, Forman D, Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther. 2006;13(7):652–658. doi: 10.1038/sj.gt.3302695. [DOI] [PubMed] [Google Scholar]

[B27] 27.Wyss BK, Donnelly AF, Zhou D, Sinn AL, Pollok KE, Goebel WS. Enhanced homing and engraftment of fresh but not ex vivo cultured murine marrow cells in submyeloablated hosts following CD26 inhibition by Diprotin A. Exp Hematol. 2009;37(7):814–823. doi: 10.1016/j.exphem.2009.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B28] 28.Peranteau WH, Endo M, Adibe OO, Merchant A, Zoltick PW, Flake AW. CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. Blood. 2006;108(13):4268–4274. doi: 10.1182/blood-2006-04-018986. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B29] 29.Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev. 2007;16(3):347–354. doi: 10.1089/scd.2007.9995. [DOI] [PubMed] [Google Scholar]

[B30] 30.Christopherson KW, 2nd, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 2007;16(3):355–360. doi: 10.1089/scd.2007.9996. [DOI] [PubMed] [Google Scholar]

[B31] 31.Kawai T, Choi U, Liu PC, Whiting-Theobald NL, Linton GF, Malech HL. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev. 2007;16(3):361–370. doi: 10.1089/scd.2007.9997. [DOI] [PubMed] [Google Scholar]

[B32] 32.Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol. 2003;31(11):1126–1134. doi: 10.1016/j.exphem.2003.07.002. [DOI] [PubMed] [Google Scholar]

[B33] 33.Christopherson KW, II, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood. 2003;101(12):4680–4686. doi: 10.1182/blood-2002-12-3893. [DOI] [PubMed] [Google Scholar]

[B34] 34.Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612–4619. doi: 10.1210/jc.2006-1009. [DOI] [PubMed] [Google Scholar]

[B35] 35.Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46(8):876–886. doi: 10.1177/0091270006289850. [DOI] [PubMed] [Google Scholar]

[B36] 36.Farag SS, Srivastava S, Messina-Graham S, et al. In-vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22(7):1007–1015. doi: 10.1089/scd.2012.0636. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B37] 37.Parker MH, Loretz C, Tyler AE, Snider L, Storb R, Tapscott SJ. Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation. Skelet Muscle. 2012;2(1):4. doi: 10.1186/2044-5040-2-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B38] 38.Blanchet X, Langer M, Weber C, Koenen RR, von Hundelshausen P. Touch of chemokines. Front Immunol. 2012;3:175. doi: 10.3389/fimmu.2012.00175. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B39] 39.Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 1999;274(7):3988–3993. doi: 10.1074/jbc.274.7.3988. [DOI] [PubMed] [Google Scholar]

[B40] 40.Struyf S, Proost P, Sozzani S, et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol. 1998;161(6):2672–2675. [PubMed] [Google Scholar]

[B41] 41.Proost P, Struyf S, Couvreur M, et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol. 1998;160(8):4034–4041. [PubMed] [Google Scholar]

[B42] 42.Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol. 1999;162(8):4903–4909. [PubMed] [Google Scholar]

[B43] 43.Wrenger S, Reinhold D, Hoffmann T, et al. The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. FEBS Lett. 1996;383(3):145–149. doi: 10.1016/0014-5793(96)00221-9. [DOI] [PubMed] [Google Scholar]

[B44] 44.Smith AG, Heath JK, Donaldson DD, et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 1988;336(6200):688–690. doi: 10.1038/336688a0. [DOI] [PubMed] [Google Scholar]

[B45] 45.Xu RH, Peck RM, Li DS, Feng X, Ludwig T, Thomson JA. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods. 2005;2(3):185–190. doi: 10.1038/nmeth744. [DOI] [PubMed] [Google Scholar]

[B46] 46.Yu P, Pan G, Yu J, Thomson JA. FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. Cell Stem Cell. 2011;8(3):326–334. doi: 10.1016/j.stem.2011.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B47] 47.Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. doi: 10.1016/j.cell.2006.07.024. [DOI] [PubMed] [Google Scholar]

[B48] 48.Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar]

[B49] 49.Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920. doi: 10.1126/science.1151526. [DOI] [PubMed] [Google Scholar]

[B50] 50.Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678–684. doi: 10.1016/j.stem.2012.05.005. [DOI] [PubMed] [Google Scholar]

[B51] 51.Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell. 2010;6(1):21–24. doi: 10.1016/j.stem.2009.12.008. [DOI] [PubMed] [Google Scholar]

[B52] 52.Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773–4777. doi: 10.1182/blood-2011-01-330514. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B53] 53.Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med. 2013;210(2):205–208. doi: 10.1084/jem.20122760. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B54] 54.Broxmeyer HE, Campbell TB, Cooper S, Hangoc G. Inhibition/Depletion of CD26/DPPIV Enhances Survival Promoting Activity of SDF-1/CXCL12 and Myelosuppressive Activities of Inhibitory Chemokines on Hematopoietic Progenitor Cells. Blood. 2007;110(Suppl Part 1):188A. (abstract #610). 2007. [Google Scholar]

[B55] 55.Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–1131. doi: 10.2337/diab.44.9.1126. [DOI] [PubMed] [Google Scholar]

[B56] 56.Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem. 1997;272(34):21201–21206. doi: 10.1074/jbc.272.34.21201. [DOI] [PubMed] [Google Scholar]

[B57] 57.Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–2350. doi: 10.1161/CIRCULATIONAHA.107.739938. [DOI] [PubMed] [Google Scholar]

[B58] 58.Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402–7405. [PubMed] [Google Scholar]

[B59] 59.Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650–19655. [PubMed] [Google Scholar]

[B60] 60.López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem. 2003;278(12):10195–10200. doi: 10.1074/jbc.M212147200. [DOI] [PubMed] [Google Scholar]

[B61] 61.Ochiai H, Okada S, Saito A, et al. Inhibition of insulin-like growth factor-1 (IGF-1) expression by prolonged transforming growth factor-β1 (TGF-β1) administration suppresses osteoblast differentiation. J Biol Chem. 2012;287(27):22654–22661. doi: 10.1074/jbc.M111.279091. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B62] 62.Nagineni CN, Samuel W, Nagineni S, et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol. 2003;197(3):453–462. doi: 10.1002/jcp.10378. [DOI] [PubMed] [Google Scholar]

[B63] 63.Renner U, Lohrer P, Schaaf L, et al. Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology. 2002;143(10):3759–3765. doi: 10.1210/en.2002-220283. [DOI] [PubMed] [Google Scholar]

[B64] 64.Zhou X, Hu H, Balzar S, Trudeau JB, Wenzel SE. MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts. J Immunol. 2012;188(12):6046–6054. doi: 10.4049/jimmunol.1102760. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B65] 65.Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–846. doi: 10.1038/nature02040. [DOI] [PubMed] [Google Scholar]

[B66] 66.Stier S, Ko Y, Forkert R, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005;201(11):1781–1791. doi: 10.1084/jem.20041992. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B67] 67.Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106(4):1232–1239. doi: 10.1182/blood-2004-11-4422. [DOI] [PubMed] [Google Scholar]

[B68] 68.Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63–74. doi: 10.1016/j.cell.2012.01.051. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B69] 69.Zhu J, Garrett R, Jung Y, et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007;109(9):3706–3712. doi: 10.1182/blood-2006-08-041384. [DOI] [PubMed] [Google Scholar]

[B70] 70.Huber BC, Brunner S, Segeth A, et al. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. Cardiovasc Res. 2011;90(3):529–537. doi: 10.1093/cvr/cvr014. [DOI] [PubMed] [Google Scholar]

[B71] 71.Grassinger J, Haylock DN, Storan MJ, et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood. 2009;114(1):49–59. doi: 10.1182/blood-2009-01-197988. [DOI] [PubMed] [Google Scholar]

[B72] 72.Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457–462. doi: 10.1038/nature10783. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B73] 73.Istvanffy R, Kröger M, Eckl C, et al. Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. Blood. 2011;118(10):2712–2722. doi: 10.1182/blood-2010-05-287235. [DOI] [PubMed] [Google Scholar]

[B74] 74.Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell. 2010;6(3):251–264. doi: 10.1016/j.stem.2010.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B75] 75.Hooper AT, Butler JM, Nolan DJ, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009;4(3):263–274. doi: 10.1016/j.stem.2009.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B76] 76.Sharifi BG, Zeng Z, Wang L, et al. Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26(6):1273–1280. doi: 10.1161/01.ATV.0000222017.05085.8e. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B77] 77.George AL, Bangalore-Prakash P, Rajoria S, et al. Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol. 2011;4:24. doi: 10.1186/1756-8722-4-24. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B78] 78.Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 2008;22(5):559–574. doi: 10.1101/gad.1636908. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B79] 79.Salcedo R, Young HA, Ponce ML, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol. 2001;166(12):7571–7578. doi: 10.4049/jimmunol.166.12.7571. [DOI] [PubMed] [Google Scholar]

[B80] 80.Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther. 2012;136(3):267–282. doi: 10.1016/j.pharmthera.2012.07.012. [DOI] [PubMed] [Google Scholar]

[B81] 81.O’Leary HA. *, Ou X*, Broxmeyer HE. The role of dipeptidyl peptidase 4 (DPP4) in hematopoiesis and transplantation. Curr Opin Hematol. 2013 doi: 10.1097/MOH.0b013e32836125ac. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types

Xuan Ou

Heather A O’Leary

Hal E Broxmeyer

Abstract

Introduction

Effects of DPP4 on HSCs and HPCs

Effects of DPP4 on leukocyte trafficking and migration

A plethora of proteins with potential DPP4 truncation sites

Table 1.

Table 2.

Table 3.

Potential effects of DPP4 on ESCs and induced pluripotent stem (iPS) cells

Models for potential effects of DPP4 truncation of proteins

Figure 1.

Figure 2.

Conclusions

Acknowledgments

Authorship

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types

Xuan Ou

Heather A O’Leary

Hal E Broxmeyer

Abstract

Introduction

Effects of DPP4 on HSCs and HPCs

Effects of DPP4 on leukocyte trafficking and migration

A plethora of proteins with potential DPP4 truncation sites

Table 1.

Table 2.

Table 3.

Potential effects of DPP4 on ESCs and induced pluripotent stem (iPS) cells

Models for potential effects of DPP4 truncation of proteins

Figure 1.

Figure 2.

Conclusions

Acknowledgments

Authorship

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases